Anti-Neoplastic Agents Market 2025

Anti-Neoplastic Agents Market Size

The global anti-neoplastic agents market reached a value of nearly $130,010.52 million in 2024, having grown at a compound annual growth rate (CAGR) of 7.21% since 2019. The market is expected to grow from $130,010.52 million in 2024 to $206,766.16 million in 2029 at a rate of 9.72%. The market is then expected to grow at a CAGR of 10.21% from 2029 and reach $336,221.00 million in 2034. Growth in the historic period resulted from the rising cancer research investment, rise of gene therapy, rise in biologics development and healthcare infrastructure development. Factors that negatively affected growth in the historic period were high R&D failure rates and toxicity in healthy cell. Going forward, the growing geriatric population, rising global cancer prevalence, rising healthcare expenditures and favorable government initiative will drive the growth. Factor that could hinder the growth of the anti-neoplastic agents market in the future include side effects and high treatment costs.

Anti-Neoplastic Agents Market Drivers

The key drivers of the anti-neoplastic agents market include: Growing Geriatric Population Growing geriatric population is expected to propel the growth of the anti-neoplastic agents market going forward. The rising geriatric population is more susceptible to developing cancer due to age-related cellular changes and weakened immune systems, increasing the demand for anti-neoplastic agents. These agents are crucial for managing cancer in older adults by offering targeted and effective treatment options that aim to minimize side effects and improve quality of life. Therefore, growing geriatric population will drive the growth of the anti-neoplastic agents market. The growing geriatric population growth contribution during the forecast period in 2024 is 2.30%.

Anti-Neoplastic Agents Market Restraints

The key restraints on the anti-neoplastic agents market include: High R&D Failure Rates During the historic period, high R&D failure rates restrained the growth of the anti-neoplastic agents market. High R&D failure rates in the anti-neoplastic agents significantly increase development costs and delay product launches, leading to reduced return on investment. This discourages innovation and limits the introduction of new, effective therapies, thereby hampering market growth. For instance, in 2023, according to the National Institutes of Health (NIH) , a US-based medical research agency, of the 54 antineoplastic drugs studied, 29 were to face a rejection risk of up to 100%. Therefore, high R&D failure rates hindered the growth of the anti-neoplastic agents market. Growth affected by high R&D failure rates during the forecast period in 2024 is -1.50%.

Anti-Neoplastic Agents Market Trends

Major trends shaping the anti-neoplastic agents market include: Advancing Cancer Treatment Through Precision Medicine Companies operating in the anti-neoplastic agents market are focusing on precision medicine approaches, such as gene fusion targeting, to develop more effective, personalized cancer therapies that address specific genetic alterations and improve treatment outcomes. Gene fusion targeting is a medicine approach that involves identifying and targeting specific genetic abnormalities formed by the fusion of two separate genes, which drive cancer growth, to enable more effective and personalized treatment. For instance, In December 2024, Merus N.V., a Netherlands-based clinical-stage oncology company, announced that the U.S. Food and Drug Administration (FDA) has approved BIZENGRI (zenocutuzumab-zbco) for adults with advanced, unresectable, or metastatic pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion who have progressed after prior therapy. Approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR), continued approval is contingent upon confirmatory trials. BIZENGRI carries a boxed warning for embryo-fetal toxicity and additional warnings for infusion-related reactions, hypersensitivity, interstitial lung disease and left ventricular dysfunction. Enhancing Treatment Precision With Targeted Therapies Major companies operating in the anti-neoplastic agents market are focusing on affordable drugs, such as generic cancer drugs and life-saving treatments, reduce healthcare costs and expand their market reach in price-sensitive regions. Generic cancer drugs are cost-effective alternatives to branded cancer medications that contain the same active ingredients, dosage and therapeutic effect, but are marketed under a different name and at a lower price once the original patent expires. For instance,n March 2024, Zydus Lifesciences, an India-based pharmaceutical company launched IBYRA, a generic version of the cancer drug Olaparib, in India. IBYRA, a next-generation PARP inhibitor, targets specific genetic mutations, particularly those related to homologous recombination deficiency (HRD), which are common in cancers like breast, ovarian, prostate and pancreatic cancers. This targeted therapy offers a more personalized and effective treatment approach, with Zydus partnering with MedGenome to provide homologous recombination deficiency (HRD) testing for patient identification.

Opportunities And Recommendations In The Anti-Neoplastic Agents Market

Opportunities – The top opportunities in the anti-neoplastic agents market segmented by type will arise in the miscellaneous segment, which will gain $22,056.75 million of global annual sales by 2029. The top opportunities in the anti-neoplastic agents market segmented by disease type will arise in the breast cancer segment, which will gain $25,762.23 million of global annual sales by 2029. The top opportunities in the anti-neoplastic agents market segmented by end user will arise in the hospitals segment, which will gain $34,081.69 million of global annual sales by 2029. The anti-neoplastic agents market size will gain the most in the USA at $28,375.08 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the anti-neoplastic agents to focus on advancing gene fusion targeting for precision oncology, focus on expanding access through affordable targeted therapies, focus on advancing HER2-targeted antibody-drug conjugates, focus on the high-growth miscellaneous segment for diversified oncology expansion, focus on the breast cancer segment to maximize high-growth returns, expand in emerging markets, continue to focus on developed markets, provide competitively priced offerings, continue to use B2B promotions, focus on clinics to capitalize on the fastest growth in anti-neoplastic demand and focus on the geriatric population to drive demand for anti-neoplastic agents.